News
4h
TipRanks on MSNElicio announces publication of ELI-002 updated AMPLIFY-201 Phase 1 dataElicio Therapeutics (ELTX) announced the publication of follow-up data from the Phase 1 AMPLIFY-201 study evaluating ELI-002 in the peer-reviewed ...
PAC business momentum continued, with ongoing ASP growth (9% in Q2 vs. 13% in Q1), but gross margin decreased to 33% from 36.4% due to commissioning-related costs. SG&A declined further, while R&D ...
9h
TipRanks on MSNEXACT Therapeutics to Present Phase 1 Trial Data at ESMO Congress 2025EXACT Therapeutics AS ( ($DE:56F) ) has shared an update. EXACT Therapeutics announced that data from its ACTIVATE Phase 1 trial, focusing on ...
Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...
The Phase 1 clinical trials program increases patients’ access to novel research by bringing it closer to their homes. Distance should never stand between you and the latest medical breakthroughs. As ...
Phase 2 of the voting closes at noon ET on July 2, with starting lineups for each league announced on July 6 at 5 PM ET on ESPN. For now, let's dig into the Phase 1 voting results.
U.S. President Donald Trump has directed federal agencies to assess China's performance under the Phase 1 trade deal that he signed with Beijing in 2020 during his first term at the White House.
We report the results of the phase 1 study of cemiplimab for expansion cohorts of patients with locally advanced or metastatic cutaneous squamous-cell carcinoma, as well as the results of the ...
Based on the preliminary Phase 1 safety results, a safety review committee comprising study staff and independent physicians concluded the compound was well tolerated by participants. Martin Low, CEO ...
Previous reviews of phase 1 oncology trials reported a rate of response to treatment of 4 to 6 percent and a toxicity-related death rate of 0.5 percent. These results may not reflect the rates in c ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results